Quantitative 3D high-resolution imaging of skeletal muscle morphology in aged lean and diet-induced obese mice
Background & aim: Effective treatment of muscle diseases requires comprehensive, multidimensional assessment of muscle structure, mass, and function. This need is particularly evident in sarcopenia, where age-related loss of muscle mass and quality drives functional decline, increased morbidity, and frailty…
Differential effects of semaglutide, tirzepatide, and survodutide on energy expenditure in obese mice under thermoneutrality
Background & aim: Obesity pharmacotherapy has significantly improved weight management, with semaglutide (GLP-1 receptor agonist), tirzepatide (dual GLP-1 and GIP receptor agonist) and survodutide (dual glucagon/GLP-1 receptor agonist) demonstrating substantial efficacy in reducing body weight. These drugs primarily act by…
Generation and characterisation of a humanised GLP-1 receptor mouse model for translational drug development
Background: Injectable peptide-based glucagon-like peptide-1 receptor (GLP1R) agonists (GLP1RAs) are effective treatments for obesity and diabetes but are limited by patient compliance and scalability challenges. In contrast, non-peptide small-molecule GLP1RAs offer the advantage of oral delivery but are relatively inactive…
Elucidating the potential benefit of pump-delivered subcutaneous GLP-1R agonist: an exploratory study in the diet-induced obese mouse
Background & aim: Subcutaneous pump delivery of the GLP1-receptor-agonist exenatide reduced body weight and improved glycemia in the DIO mouse. Basal-bolus administration conferred advantage over basal alone. This mode of incretin-based therapy offers an alternative to conventional intermittent dosing and…
Metabolic effects of survodutide in DIO mice at thermoneutrality
Background & aim: Survodutide is a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), currently in clinical development for obesity and related metabolic disorders. By concurrently enhancing GCGR and GLP1R signaling, survodutide offers a synergistic approach…
Metabolic Effects of Tirzepatide and Semaglutide: Energy Expenditure and Adaptations During and After Treatment
Background & aim: Obesity pharmacotherapy has significantly improved weight management, with semaglutide (GLP-1 receptor agonist) and tirzepatide (dual GLP-1 and GIP receptor agonist) demonstrating substantial efficacy in reducing body weight. These drugs primarily act by suppressing appetite and improving glucose…
